Seres Therapeutics
MCRB
119 hedge funds and large institutions have $672M invested in Seres Therapeutics in 2022 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 51 increasing their positions, 28 reducing their positions, and 25 closing their positions.
115% more capital invested
Capital invested by funds: $313M → $672M (+$359M)
82% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 28
77% more call options, than puts
Call options by funds: $2.31M | Put options by funds: $1.31M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.71% less ownership
Funds ownership: 4.93% → 4.22% (-0.71%)
3% less funds holding
Funds holding: 123 → 119 (-4)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$44.7M |
| 2 |
Janus Henderson Group
London,
|
+$29.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$11.6M |
| 4 |
EP
Eversept Partners
New York
|
+$9.91M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$9.34M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
-$3.96M |
| 3 |
Millennium Management
New York
|
-$3.75M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.6M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$2.39M |
MCRB Hedge Fund Activity: Q3 2022 in Review
119 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q3 2022, worth a combined $672M — up 115% from $313M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of MCRB and 21 opened new positions — a net loss of 4 holders — while 28 trimmed existing stakes and 51 added.
The largest buyer was Flagship Pioneering, adding an estimated $44.7M. The largest seller was CVI Holdings, exiting entirely with an estimated $9.34M sold.
- 119 institutional investors held Seres Therapeutics (MCRB) as of Q3 2022, down from 123 in Q2 2022.
- Funds reported $672M of Seres Therapeutics stock for Q3 2022, up 115% quarter-over-quarter.
- 21 funds opened new Seres Therapeutics positions in Q3 2022 and 25 closed out, a net change of -4 holders.
- The largest Seres Therapeutics buyer in Q3 2022 was Flagship Pioneering, an estimated $44.7M added.
- The largest Seres Therapeutics seller in Q3 2022 was CVI Holdings, an estimated $9.34M sold.
Based on aggregated 13F filings for Q3 2022.